DGAP-News: REVA Appoints Managing Director International

        Print
| Source: EQS Group AG
REVA Medical, Inc. 

14.05.2013 03:12
---------------------------------------------------------------------------

SAN DIEGO, 2013-05-14 03:12 CEST (GLOBE NEWSWIRE) --
REVA Medical, Inc. (ASX:RVA) ('REVA' or the 'Company') is pleased to announce
that Michel Vanbrabant has been appointed Managing Director International for
the Company. In this role, he will be responsible for commercial planning
activities leading up to the launch of REVA's drug-eluting bioresorbable
coronary scaffold in international markets, which is anticipated to occur
toward the end of 2014. He will be based in Brussels, Belgium. 

Mr. Vanbrabant has extensive experience commercializing medical devices
internationally. He spent more than ten years at Guidant Corporation (now
Abbott Laboratories) where he began as a sales representative for Vascular
Intervention and held increasing roles of responsibility in sales, marketing,
and management before becoming Vascular Intervention Country Manager for
France. He then joined St. Jude Medical Corporation as Marketing Director for
the Cardiology Division, responsible for Europe, the Middle East, Asia and
Canada ('EMEAC') before being appointed Senior Director for the Neuromodulation
Division, EMEAC. Mr. Vanbrabant most recently served as Vice President of Sales
& Marketing Europe for PneumRx, Inc., a privately held early stage company,
where he led the successful commercial launch of PneumRx's minimally invasive
implants for patients suffering from emphysema. 

'We are extremely pleased to have attracted such an exceptional individual as
Michel to assist REVA with establishing the foundation for commercial sales of
REVA's bioresorbable scaffold in international markets,' commented Bob
Stockman, REVA's Chairman and Chief Executive Officer. 'As we move toward
European CE Marking, Michel will work with our executive team to formulate the
detailed commercial plans for our scaffold, with specific focus on sales,
distribution, and reimbursement. We look forward to introducing Michel to our
clinical and industry associates at the EuroPCR being held in Paris, France,
May 21st through 24th.' 

About REVA

REVA is a development stage medical device company incorporated in Delaware,
USA, that is focused on the development and eventual commercialization of its
proprietary bioresorbable stent products. The ReZolve(r) product family, which
is 
in a clinical study phase, combines REVA's proprietary stent design with a
proprietary polymer that is metabolized and cleared from the body. REVA's
anticipated commercial product, the ReZolve2 scaffold, is designed to offer
full x-ray visibility, clinically relevant sizing, and a controlled and safe
resorption rate. In addition, by early encapsulation of the stent in the artery
tissue coupled with the loss of scaffold structure over time, the ReZolve2
scaffold may reduce the incidence of late forming blood clots or otherwise
reduce long-term disease progression, potential benefits of bioresorbable
scaffolds that have yet to be proven. REVA will require clinical results and
regulatory approval before it can begin selling the ReZolve2 scaffold. 

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are
based on management's beliefs, assumptions and expectations and on information
currently available to management. All statements that are not statements of
historical fact, including those statements that address future operating
performance and events or developments that we expect or anticipate will occur
in the future, are forward-looking statements, such as those statements
regarding our ability to obtain the regulatory approvals required to market our
ReZolveO scaffold, our ability to timely and successfully complete our clinical
trials, our ability to protect our intellectual property position, our ability
to commercialize our products if and when approved, our ability to develop and
commercialize new products, and our estimates regarding our capital
requirements and financial performance, including profitability. You should not
place undue reliance on these forward-looking statements. Although management
believes these forward-looking statements are reasonable as and when made,
forward-looking statements are subject to a number of risks and uncertainties
that may cause our actual results to vary materially from those expressed in
the forward-looking statements, which risks and uncertainties are described in
the 'Risk Factors' section of our Annual Report on Form 10-K filed with the
United States Securities and Exchange Commission (the 'SEC') on February 27,
2013. Any forward-looking statements in this announcement speak only as of the
date when made. REVA does not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise. 


         CONTACT: United States
         
         Investor and Media Enquiries:
         Cheryl Liberatore
         Director, Investor Relations and Marketing
         REVA Medical, Inc.
         +1 858 966-3045
         
         Australia
         
         Investor Enquiries:
         Kim Jacobs
         Inteq Limited
         +61 2 9231 3322
         
         Media Enquiries:
         Haley Price or Rebecca Wilson
         Buchan Consulting
         +61 3 9866 4722
News Source: NASDAQ OMX



14.05.2013 Dissemination of a Corporate News, transmitted by DGAP - 
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      REVA Medical, Inc.
              
               
              United States
Phone:        
Fax:          
E-mail:       
Internet:     
WKN:          
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------